For most people with Crohn's disease, the honest answer to "can I stop my medication now that I am in remission?" is: not on your own, and not without a plan. Crohn's disease is a chronic, relapsing inflammation of the gut, and the studies that follow people after treatment is withdrawn show relapse in roughly 4 in 10 people within one to two years of stopping a biologic. Some people with long, deep remission do step treatment down, but they do it under their IBD team, with stool, blood and scope or scan checks and a written plan for restarting. This guide explains what the research actually found, drug by drug, and who gets considered.
If you are asking because you feel well, are tired of infusions or injections, worry about side effects, or are struggling with cost, you are in good company, and the question is a legitimate one. Nothing here is a recommendation to stop, start, switch, taper or ration any medicine. It is a plain-English map of the evidence so you can walk into the conversation with your gastroenterologist better prepared. Where the evidence is thin or contested, we say so. If you have your own version of the UC question, see our companion guide on living without medication with ulcerative colitis; this one is Crohn's only, because the numbers and the drug that matters most are different.
Can you stop Crohn's medication if you are in remission?
For most people, no, not safely on their own. The best evidence is that relapse after stopping is common: a meta-analysis of 37 studies found a pooled relapse rate of 43% after stopping an anti-TNF drug in Crohn's disease (Dai 2023). A small group with sustained, documented remission do stop under supervision, and guidelines allow it as an individual decision, not a default.
It helps to separate two things that get blurred online. One is "stopping because I feel fine", which is a personal experiment with a real chance of relapse. The other is "de-escalation", a structured conversation between you and your IBD team that happens when remission has been confirmed by tests, not just by how you feel, and that comes with a restart plan. The British Society of Gastroenterology guideline suggests that anti-TNF therapy may be withdrawn in people with prolonged steroid-free remission and mucosal healing, but it grades that as a weak recommendation based on very low-quality evidence and says decisions should be individualized (Lamb 2019).
So there is no universal rule of the form "after X years you can stop". The people who describe a successful stop in patient forums almost always describe the second path: a gastroenterologist who raised it, a pile of normal results, and a named way back.
What do people in r/CrohnsDisease say about coming off meds?
The dominant message in the community is cautious, sometimes blunt. In one widely upvoted thread, people respond with alarm to the idea that someone claiming you can eventually be taken off meds with enough care is trustworthy, and several describe a doctor who raised the possibility only after many years of remission and told them not to count on it (r/CrohnsDisease). Others describe stopping for personal or insurance reasons and a flare that followed.
In a thread from someone newly diagnosed and asking whether meds are forever, the most upvoted replies say that for most people treatment continues, that mild disease today does not promise mild disease later, and that diet may help symptoms but is not enough to treat the underlying disease (r/CrohnsDisease). A smaller number mention a friend or relative who stays well without drugs, which is worth acknowledging: it happens, but it is the exception, and nobody can tell in advance who will be the exception. A separate thread from a young person worried about stopping everything because of cost drew mostly gentle advice to look for help with the price before touching the dose (r/CrohnsDisease). A longer-running thread asks whether we ever get to stop (r/CrohnsDisease), and one worry that recurs there is that a gap in treatment might make a drug work less well later.
These are anecdotes from self-selected posters, so use them for company and vocabulary, not for medical decisions. The research below addresses that last worry directly, and the answer is more nuanced than either side of the argument.
What happens when you stop a biologic for Crohn's?
After stopping an anti-TNF biologic such as infliximab or adalimumab, around 4 in 10 people with Crohn's relapse within a few years, but most who restart regain remission. A 2023 meta-analysis found 38% relapsed at 1 to 2 years and 53% at 3 to 5 years, with re-treatment working again in 76% (Dai 2023).
Other pooled analyzes land in the same place. A UK study of 146 people with Crohn's withdrawn from anti-TNF for sustained remission found relapse in 36% by one year and 56% by two years. Pooling every published cohort, the one-year relapse estimate for Crohn's was 39%, and re-treatment worked in 88% (Kennedy 2016). A systematic review of 27 studies found 44% relapse overall after stopping anti-TNF in Crohn's (Gisbert 2015). A wider review of 69 studies concluded that about 50% of people who stop anti-TNF agents after combination therapy are still in remission two years later, and that the share falls over time (Torres 2015).
Note what these figures are. They describe groups, mostly people who had been in remission for at least a year, and they come from cohort studies rather than randomized trials, because withdrawal is hard to randomize. The Cochrane review of withdrawal found no randomized trial of stopping a biologic on its own, only trials of stopping azathioprine, alone or from a combination with infliximab (Boyapati 2018). The British guideline makes the same point: all the published data so far come from cohort studies, and data on newer biologics are awaited (Lamb 2019).
That last point matters if you take something other than infliximab or adalimumab. Everything above concerns anti-TNF drugs. We could not find comparable withdrawal data for the other biologic classes or for small-molecule tablets, so no number here can be transferred to them. For upadacitinib, the placebo-withdrawal arms of its Crohn's and colitis trials are summarized in what happens if you stop Rinvoq. If you are reading this because a biologic seems to be losing its effect rather than because you want to stop, start with what it means when a biologic stops working and how often people switch biologics for Crohn's.
What did the STORI study find?
STORI is the landmark Crohn's withdrawal study, and its headline is that about 4 in 10 relapsed within a year, but a low-risk subgroup did far better. In 115 people on infliximab plus an antimetabolite and in steroid-free remission for at least 6 months, infliximab was stopped. Over a median 28 months, 52 relapsed; the one-year relapse rate was 43.9% (Louis 2012).
What made STORI influential is the risk model. Factors linked to relapse after stopping infliximab were male sex, no previous bowel resection, a white cell count above 6.0, hemoglobin at or below 145 g/L, C-reactive protein of 5.0 mg/L or higher, and fecal calprotectin of 300 micrograms per gram or higher. People with no more than two of these factors, about 29% of the study group, had a 15% risk of relapse within a year. Re-treatment with infliximab was effective and well tolerated in 88% of people who relapsed (Louis 2012).
Read that carefully. It does not say that 29% of people with Crohn's can stop. It says that within a group already chosen for long remission on combination therapy, a handful of ordinary lab values separated the lower-risk people from the rest. It is also a single cohort from 2012, and the reason these markers matter is a lesson in itself: calprotectin and CRP are exactly the kind of numbers you can follow over time.
What did the SPARE trial find about stopping infliximab or the immunosuppressant?
SPARE is the first large randomized test of de-escalation in Crohn's, and it found that stopping infliximab raised relapse risk while stopping the immunosuppressant did not. It enrolled 211 adults in steroid-free remission on infliximab plus an immunosuppressant and randomized them to continue both, stop infliximab, or stop the immunosuppressant. Two-year relapse rates were 14% for combination, 36% for stopping infliximab and 10% for stopping the immunosuppressant (Louis 2023).
The authors reported a hazard ratio of 3.45 for infliximab withdrawal against continuing combination therapy. Of the people who relapsed and were retreated per protocol, 25 of 28 regained remission, including 22 of 23 in the infliximab withdrawal group. Time spent in remission over two years was similar across the groups, and serious adverse events did not differ, with no deaths or malignancies. Their conclusion was that infliximab withdrawal should only be considered after careful assessment of risks and benefits for each person, whereas stopping the immunosuppressant could generally be the preferable de-escalation strategy (Louis 2023).
Three limits are worth knowing. The trial was open-label, so participants and doctors knew who stopped what. It included only people already on combination therapy, so it says nothing about people on a biologic alone. And "time in remission" being similar does not mean a relapse feels like nothing: a flare is a flare, even if the drug works again. The same research group later tested blood protein markers for predicting relapse in the STORI and SPARE cohorts and found that distinct profiles tracked short-term and later relapse, with better discrimination than CRP or fecal calprotectin alone, but these are research tools, not something your clinic can order today (Pierre 2024).
What happens if you stop azathioprine or another immunomodulator?
After stopping azathioprine alone, relapse is common and tends to rise over the years. In a French follow-up of 66 people who stopped azathioprine after a median of 63.6 months of remission, cumulative relapse was 14% at 1 year, 52.8% at 3 years and 62.7% at 5 years. Higher CRP, lower hemoglobin and a higher neutrophil count predicted relapse, and nearly everyone retreated with azathioprine regained remission (Treton 2009).
The Cochrane review pooled four randomized trials of stopping azathioprine monotherapy in quiescent Crohn's. Relapse occurred in 32% of people who stopped versus 14% who continued (low-quality evidence). In two trials of people on combination therapy, relapse was about the same whether azathioprine was stopped or continued, around 49% and 48% (very low-quality evidence) (Boyapati 2018). That is consistent with SPARE: the immunosuppressant adds less once an anti-TNF is on board.
A 2025 meta-analysis of 22 studies across IBD found a pooled relapse rate of 32.5% after azathioprine withdrawal, lower in Crohn's (24.7%) than ulcerative colitis (41.3%), with low to very low certainty. Shorter azathioprine duration, raised CRP and a lack of mucosal healing were linked to relapse (Al Abdulqader 2025). The wide spread of figures across studies is partly because they mix populations, definitions and follow-up times. The British guideline quotes a range of 16.5% to 53% at 12 months in Crohn's and 63% to 85% at 5 years after thiopurine withdrawal, and suggests that people in prolonged remission with mucosal healing may stop after discussing the risks and benefits, noting that the risk of relapse should be weighed against longer-term thiopurine risks including infections and cancer (Lamb 2019).
On those risks: in a French cohort of 19,486 people with IBD, lymphoproliferative disorders occurred at 0.90 per 1,000 patient-years in people taking thiopurines, versus 0.26 in people who never took them and 0.20 in those who had stopped (Beaugerie 2009). The absolute risk is low, but it is the reason a thiopurine is sometimes the drug a team talks about reducing first, particularly in older people, and why that conversation is individual.
Which stopping studies apply to which medicine?
The evidence differs by drug, so a one-line answer in either direction is wrong for almost everyone. This table summarizes the headline numbers above. All are group averages, none describes you, and none is a recommendation.
| Medicine or strategy | What happened after withdrawal | Certainty and caveats |
|---|---|---|
| Anti-TNF (infliximab, adalimumab) stopped | 43% pooled relapse; 38% at 1 to 2 years, 53% at 3 to 5 years; 76% regained remission on re-treatment (Dai 2023) | Cohort data; anti-TNF only; heterogeneous |
| Infliximab stopped, still on immunosuppressant | 36% relapse at 2 years vs 14% on combination (Louis 2023) | Randomized but open-label |
| Immunosuppressant stopped, still on infliximab | 10% relapse at 2 years, similar to combination (Louis 2023) | Only for people on both drugs |
| Azathioprine alone stopped | 32% vs 14% relapse in trials (Boyapati 2018); 62.7% at 5 years in one cohort (Treton 2009) | Low-quality evidence |
| Stopping after deep remission | 34.1% at 1 year and 39.9% at 2 years in Crohn's (Zhang 2020) | 7 Crohn's studies; mixed drugs |
| Other biologic classes and small molecules | No comparable withdrawal data found | Not covered by these studies |
Does deep remission change the answer?
A little, but not as much as people hope. Deep remission, defined as clinical remission plus mucosal healing, lowers the average relapse risk but does not remove it. A meta-analysis of 13 studies with 837 people in deep remission found 28.7% relapsed within one year and 38.4% within two after de-escalation. For Crohn's alone it was 34.1% and 39.9%, and when the drug stopped was an anti-TNF, 29.8% relapsed within a year and 41.4% within two. Re-escalation recaptured response in 75.4%. The authors concluded that combined clinical and endoscopic remission should not by itself be a reason to consider de-escalation (Zhang 2020).
The anti-TNF meta-analysis tells a similar story: when studies required only clinical remission before stopping, Crohn's relapse was 45%; when they required clinical remission and endoscopic healing, it fell to 36% (Dai 2023).
Who is more likely to relapse after stopping?
Relapse after stopping is more likely in younger people, smokers, people with longer disease, perianal fistulas, anemia, and raised CRP or calprotectin. The British guideline lists these factors, and adds that people on escalated anti-TNF doses, or taking one to prevent recurrence after surgery, had a risk above 75% on withdrawal (Lamb 2019).
The same guideline notes that persistent abnormalities on MR enterography in people who look healed at colonoscopy also make relapse more likely, and that mucosal healing, and in some studies low drug levels, are linked to lower risk. A systematic review put the one-year relapse risk after anti-TNF withdrawal at 26% with mucosal healing and 42% without across IBD, while stressing that not every study agreed (Gisbert 2015). In the UK cohort, Crohn's relapse was associated with diagnosis before age 22 (hazard ratio 2.78), a higher white cell count (3.22) and fecal calprotectin above 50 micrograms per gram (2.95) at the time of stopping, while neither continued immunomodulators nor endoscopic remission predicted outcome (Kennedy 2016).
Two honest cautions follow. First, the lists vary between studies, which is why the guideline says decisions must be individualized and that there is insufficient evidence on which clinical factors predict relapse (Lamb 2019). Second, in the other direction, the guideline describes patient profiles that favor stopping: older people without previous complications or surgery and with no sign of active inflammation, people with other conditions that raise infection risk, people with undetectable drug levels, and practical reasons such as the burden of injections. An expert review of the arguments for stopping adds side effects, loss of response over time, patient preference and cost, and argues that stopping anti-TNF may have a favorable benefit to risk ratio in the subgroup with endoscopic and biological remission (Louis 2022). The same author is clear that these relapse numbers mean stopping should not be proposed systematically.
Can you feel fine and still have Crohn's inflammation?
Yes. Symptoms and inflammation overlap but are not the same thing, which is why "I feel normal" cannot be the test for stopping a drug. The STRIDE-II consensus sets endoscopic healing as a long-term treatment target in IBD, alongside clinical remission, precisely because symptoms alone are an unreliable guide (Turner 2021).
The American Gastroenterological Association guideline on biomarkers in Crohn's disease gives a practical version of this. In people in symptomatic remission, it suggests a biomarker and symptom-based monitoring strategy over symptoms alone. A fecal calprotectin below 150 micrograms per gram together with a normal CRP rules out active inflammation, but elevated biomarkers in this setting merit confirmation with endoscopy before treatment is changed (Ananthakrishnan 2023). In other words, even a "high" result is a prompt for a look, not a verdict. For the opposite puzzle, see high calprotectin but no symptoms, and for how to tell a flare from an ordinary bad week, how to tell if you are in a Crohn's flare.
Is relapse after stopping actually a big deal?
It can be, even though most people regain remission. The Cochrane review frames the worry plainly: stopping may bring disease relapse, drug desensitization, bowel damage and need for surgery, and the review found it uncertain whether new Crohn's complications differed between groups because the evidence was low quality (Boyapati 2018). That is "we do not know", not "it is fine".
Practically, a relapse tends to mean a stretch of symptoms, tests, possibly steroids, and time to get back to remission once the drug restarts. The British guideline notes the concept of cyclical biologic use, stopping when deep remission is established and restarting at a pre-clinical relapse, but says there is no evidence yet that it is safe or cost-effective (Lamb 2019). That is a good reminder that "stop and restart if it goes wrong" is a hope, not a validated strategy for everyone.
There is also evidence that watching biomarkers closely changes outcomes in the other direction. In the CALM trial of people with early, moderate to severe Crohn's, escalating treatment based on symptoms plus calprotectin and CRP led to mucosal healing at week 48 in 46% versus 30% with symptom-based decisions (Colombel 2017). CALM is about escalation, not stopping, but it shows why modern Crohn's care leans on objective markers and why any step-down should too.
How do doctors check whether stopping is safe?
They use objective tests repeated over time, not just how you feel. Fecal calprotectin, a stool marker of gut inflammation, is the most common non-invasive check: in a meta-analysis of prospective studies (354 of the 672 people had Crohn's), it predicted relapse of quiet IBD with a pooled sensitivity of 78% and specificity of 73% (Mao 2012). That is good but imperfect: roughly 1 in 5 relapses is missed and roughly 1 in 4 quiet patients is flagged.
The British guideline suggests people who stop anti-TNF therapy should be observed for relapse, that calprotectin may help because it can rise before symptoms, and that serial measurements offer a chance to escalate before symptoms develop, though prospective evidence for acting on that is lacking. It adds that calprotectin should not be measured routinely in everyone but targeted to people with significant concerns about stopping (Lamb 2019). Practice varies by clinic, so ask what your team would do.
A supervised step-down, where one is considered, usually has these ingredients, drawn from the guidelines and studies above:
- Prolonged, documented remission. Steroid-free symptoms, normal CRP and calprotectin, and mucosal healing on colonoscopy, with imaging where your team uses it, for years rather than months.
- A named safety net. Which drug, if any, stays in place, and what happens if inflammation returns.
- Scheduled tests. Calprotectin and blood tests at agreed intervals, plus planned colonoscopy or imaging. See how often to have a colonoscopy with Crohn's and intestinal ultrasound versus colonoscopy.
- A restart rule. Written agreement about which result or symptom triggers a call and a treatment review.
- Surveillance as normal. Cancer screening continues on its own timetable, and blood tests tied to your drugs continue too; see why you need blood tests on a biologic.
Will the medicine work again if you restart it?
Usually, according to the studies, but not always, and it is a prescriber's call. A meta-analysis found re-treatment with the same anti-TNF drug induced remission again in 76% of people with Crohn's (Dai 2023). In STORI, re-treatment worked and was well tolerated in 88% (Louis 2012), and in SPARE, 22 of 23 people who relapsed after stopping infliximab regained remission (Louis 2023). A 2020 meta-analysis of de-escalation in deep remission reported response recapture of 75.4% (Zhang 2020).
Those numbers are reassuring, but they are the best case. They describe people who restarted promptly and under supervision, in studies where results were collected carefully. They do not tell you whether you personally would respond, how long it would take, or what you would go through in the meantime. If a drug does stop working, there are options; see what to do when all biologics fail in Crohn's.
What if cost or side effects are why you want to stop?
Tell your IBD team before you cut, space or skip doses. Cost and side effects are the most common practical reasons people consider stopping, and both have routes that do not involve going without treatment. This section is US-first; other countries differ.
In the US, common routes are the drug maker's patient assistance program (separate from the copay card, which generally needs commercial insurance), nonprofit grants, hospital financial assistance and your clinic's social worker or pharmacist, who often know which forms to fill in. We walk through the steps in how to afford IBD medication, written for UC but covering the same drug-maker and insurance routes. In other countries, people in the r/CrohnsDisease threads mention concession cards and compassionate supply schemes, which vary by country and drug, so check with your pharmacist and clinic rather than a forum.
If side effects are the issue, say so plainly. There may be a different drug, dose timing or monitoring plan, and the SPARE results suggest some people on two drugs may be offered a lower-burden option. That is a conversation to have with your team, not a reason to stop silently. If you suspect diet could replace treatment, our guide on whether you can control Crohn's with diet alone covers what the evidence supports.
How can tracking help before and after any medication decision?
A dated record turns "I feel fine" into evidence you and your team can read. If a step-down is ever on the table, the useful things to record are stools per day, nights woken, blood or mucus, pain, weight, doses actually taken and your calprotectin and CRP results, with the date each was done. Numbers beat adjectives in a clinic room, and a record of when symptoms drifted from your baseline makes a restart rule easier to apply.
A symptom tracker such as Clairop can capture those fields in a few taps and calculates the Harvey-Bradshaw Index from answers you have already given, with lab results and medication adherence shown on a one-page report for your appointment; see how it works. It is iPhone only, relies on what you enter, and is not a medical device, so it cannot judge inflammation or decide anything about your medicine. It supports the conversation; calprotectin, blood tests and scopes still do the measuring.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
What should you ask your gastroenterologist?
Bring specific questions and ask for the answers in numbers. Our guide to questions to ask your doctor about Crohn's disease and the list below are a start:
- Is my remission confirmed by tests, and when was my last colonoscopy or scan and calprotectin?
- Which of my drugs is the main one holding the disease quiet?
- If we ever discuss stepping down, which drug first, and what would we monitor?
- What result or symptom would mean we restart, and how fast could I restart?
- Do I have risk markers for relapse (perianal disease, smoking, previous surgery, raised markers)?
- What is my plan for blood tests and cancer surveillance regardless of what we decide?
- If the problem is cost, who in the clinic can help with assistance programs?
Which myths about stopping Crohn's medication cause the most trouble?
- "Feeling well means the disease is gone." Symptoms and inflammation can part ways, which is why guidelines pair symptoms with biomarkers (Ananthakrishnan 2023).
- "If I relapse I can just restart." Often true in studies, but a flare comes first and results are averages (Dai 2023).
- "Stopping the smallest drug is the same as stopping everything." In SPARE the outcomes of stopping infliximab and stopping the immunosuppressant were very different (Louis 2023).
- "Years of remission means I am safe to stop." Even after about five years of remission, many people relapse after stopping azathioprine (Treton 2009).
- "Never stopping is the only safe answer." Guidelines allow individualized withdrawal after prolonged remission with mucosal healing (Lamb 2019). The answer is supervised, not absolute.
When should you see a doctor promptly?
If you have stopped or missed doses, or are considering it, see your IBD team promptly if you notice blood in your stool, new or worse abdominal pain, fever, vomiting, unexplained weight loss, night-time symptoms, a swelling or discharge near the anus, or symptoms outside the gut such as a painful red eye or swollen joints. Severe pain, repeated vomiting or a rigid, swollen abdomen need urgent care. Do not wait for a routine appointment.
The bottom line
Stopping Crohn's medication in remission is not a lifestyle choice you can test safely on your own, and it is not an impossible fantasy either. The studies show that about 4 in 10 people relapse within a year or two of stopping a biologic, that most who restart do regain remission, and that who you are, which drug you stop and what your tests show matter more than any average. If you want to explore it, the next step is not a taper. It is a booked appointment, a list of results to bring and a plan written down before anything changes.




